SynthesisNIHR open research2024
Health economic studies of antimicrobial stewardship programmes: A scoping review.
Synthesis in NIHR open research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmacists in OPAT: a systematic review and meta-analysis.The Journal of antimicrobial chemotherapy · 2026Pooled it
- Pharmacoeconomic evaluation of an antimicrobial stewardship program in a tertiary care hospital of Sindh, Pakistan.Pakistan journal of medical sciences · 2026Article
- Leadership at the front line: embedding antimicrobial stewardship through the BSAC LEAP initiative.JAC-antimicrobial resistance · 2025Review
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: To conduct a scoping review of health economic evaluations of antimicrobial stewardship programmes (ASP). Our purpose was to summarise findings and to review different approaches taken. Methods: We reviewed economic evaluation studies retrieved from a number of sources, assessing the costs and effects of ASP. We described and synthesised data from studies published between 2002 and 2023 that included measures of both costs and effects/benefit of interventions. Results: Eight studies met the inclusion criteria. Six studies estimated cost-effectiveness, and two studies assessed cost utility. We found no cost-benefit studies. One of the studies was based on a randomised controlled trial. None of the studies took a broad perspective to include societal benefits that might arise from less resistant organisms on the environment contingent on reductions of prescriptions of broad-spectrum antibiotics. Conclusion: Limited evidence on the cost-effectiveness of Antimicrobial Stewardship Interventions studies suggests that the implementation of strategies to reduce antimicrobial resistance is worth the investment. However, producing a summary measure of ASP interventions is limited not just by the paucity of studies, but also heterogeneity of intervention types, variation in the implementation contexts and different methodological approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.